PDI loses another pharma contract

Share this article:
Contract sales provider PDI said Sanofi-Aventis would end its $20 million sales agreement with the firm, effective Dec. 1. It was set to expire Dec. 31, PDI said.

The end of the firm's Sanofi-Aventis deal comes a month after GlaxoSmithKline decided not to renew a $65 million to $70 million contract with PDI for 2007.

In April, AstraZeneca also ended a $65 million-$70 million agreement with PDI, affecting approximately 800 field reps.

PDI “has been significantly impacted” as the world's top pharma companies re-evaluate their commercial models, CEO Michael Marquad said in a statement.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.